Protagenic Therapeutics, Inc.\new Other Nonoperating Expense
Protagenic Therapeutics, Inc.\new (PTIX) reported Other Nonoperating Expense of $239.19 thousand for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2021-08-16
- Protagenic Therapeutics, Inc.\new other nonoperating expense for the quarter ending 2021-06-30 was $239.19K, a 335.33% increase year-over-year.
- Protagenic Therapeutics, Inc.\new other nonoperating expense for the quarter ending 2021-03-31 was $83.94K, a 115.30% increase year-over-year.
- Protagenic Therapeutics, Inc.\new other nonoperating expense for the quarter ending 2020-12-31 was $93.42K.
- Protagenic Therapeutics, Inc.\new other nonoperating expense for the quarter ending 2020-09-30 was $58.83K.
- Protagenic Therapeutics, Inc.\new other nonoperating expense for fiscal 2020 was $246.18K, a 1449.65% increase from fiscal 2019.
- Protagenic Therapeutics, Inc.\new other nonoperating expense for fiscal 2019 was $15.89K.
- Protagenic Therapeutics, Inc.\new other nonoperating expense for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- Protagenic Therapeutics, Inc.\new other nonoperating expense for fiscal 2014 was $5.00K.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 6 month | Other Nonoperating Expense 9 month | Other Nonoperating Expense 12 month |
|---|---|---|---|---|
| 2021-06-30 | $239.19K 10-Q · filed 2021-08-16 | $323.13K 10-Q · filed 2021-08-16 | $416.55K derived: sum of 3 quarters · filed 2021-08-16 | $475.38K derived: sum of 4 quarters · filed 2021-08-16 |
| 2021-03-31 | $83.94K 10-Q · filed 2021-05-17 | $177.36K derived: sum of 2 quarters · filed 2021-05-17 | $236.19K derived: sum of 3 quarters · filed 2021-05-17 | $291.13K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-12-31 | $93.42K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $152.25K derived: sum of 2 quarters · filed 2021-03-25 | $207.19K derived: sum of 3 quarters · filed 2021-08-16 | $246.18K 10-K · filed 2021-03-25 |
| 2020-09-30 | $58.83K 10-Q · filed 2020-11-16 | $113.77K derived: sum of 2 quarters · filed 2021-08-16 | $152.76K 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $54.94K 10-Q · filed 2021-08-16 | $93.93K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $38.99K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $15.89K 10-K · filed 2021-03-25 | |||
| 2015-06-30 | $0.00 10-K · filed 2015-09-25 | |||
| 2014-06-30 | $5.00K 10-K · filed 2015-09-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |